secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001558370-24-014642
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q3 revenue $70.8M, UDENYCA up 30% QoQ; net loss narrows to $10.8M from $39.6M YoY
--------------------------------------------------------------------------------

- Net revenue $70.8M; UDENYCA $66.1M (+30% QoQ, +100% YoY); LOQTORZI $5.8M (+54% QoQ).
- Net loss $10.8M ($0.09 loss per share) vs $39.6M loss in Q3 2023; non-GAAP net loss $1.7M.
- UDENYCA supply: CMO resumes production; backlog ~120k units expected by year-end; new CMO testing, commercial supply Q1 2025.
- Pipeline: Phase 2 HCC study of casdozokitug+toripalimab+bevacizumab opening; CHS-114 Phase 1 data expected H1 2025.
- Gross profit improved on divested products (CIMERLI, YUSIMRY); SG&A down $13.5M YoY on lower headcount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024014642/0001558370-24-014642-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024014642/chrs-20241106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-014642

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer